CD8A and neoplasm: It inhibits mitochondrial complex I and mTOR signaling, thereby lowering systemic glucose utilization, enhancing CD8+ T cell-mediated tumor clearance, and improving the efficacy of anti-PD-1 immune checkpoint blockade (206).